SUMMARY The effect of reperfusion achieved by early intracoronary streptokinase in acute myocardial infarction on left ventricular function was studied in 533 patients enrolled in a prospective randomised multicentre study. Two hundred and sixty four patients were allocated to conventional treatment and 269 patients to thrombolysis. At the end of the procedure patency of the infarct related vessel was achieved in 198 (85%) of 234 patients in whom coronary angiography was performed. The median interval from onset of symptoms till the angiographic documentation of patency was 200 minutes. Data were analysed according to the original treatment allocation. Global left ventricular ejection fraction was determined by radionuclide angiography in 418 patients within two days of admission, in 361 patients after two weeks, and in 307 patients after three months. Global left ventricular function remained unchanged throughout the observation period in the control group, whereas it improved during the first two weeks in patients allocated to thrombolytic treatment. Improved function in these patients persisted up to three months after the infarction. Global left ventricular ejection fraction was significantly better in the thrombolysis group than in the control group at two days, two weeks, and at three months. In patients with anterior myocardial infarction the left ventricular ejection fraction was 9% better than in the control group at two weeks and at three months. In the patients with inferior myocardial infarction differences between the two treatment groups were smaller because of photon attenuation within the body. Angiographic evidence suggested that the improvement in function seen after thrombolysis is indeed associated with the patency of the infarct related artery.
Improvement in left ventricular function after thrombolytic treatment in myocardial infarction
In approximately 80% of patients with acute myocardial infarction, recanalisation of the infarct related coronary artery, which is usually occluded, can be achieved by intracoronary administration of streptokinase. Although data from earlier small randomised trials were inconclusive,I7 the trial conducted by the Netherlands Interuniversity Cardiology Institute showed that recanalisation, which was achieved in 85% of patients, reduced by 30% the infarct size as estimated by myocardial enzyme release, preserved global left ventricular function as measured by contrast angiography, and improved one year survival. [8] [9] [10] In addition to these measurements, radionuclide angiography was performed early after admission, at the time of hospital discharge, and after three months. These radionuclide studies demonstrated that the beneficial effects of thrombolytic treatment on left ventricular ejection fraction persisted for at least three months.
Patient selection and study protocol
From June 1981 till March 1985, 533 patients were enrolled at five hospitals in a trial to compare conventional treatment and a strategy aimed at early recanalisation by intracoronary administration of streptokinase. Patient selection, study protocol, and procedures have been described in detail. [8] [9] [10] [11] [12] Briefly, patients under 71 years of age who had typical chest pain for >20 minutes and electrocardiographic signs of myocardial infarction were eligible for this trial if they were admitted to the coronary care unit within four hours of the onset of chest pain. Exclusion criteria were: previous treatment with streptokinase or bypass surgery of the infarct related vessel, a high risk for bleeding such as recent trauma, traumatic resuscitation, haematuria, and pregnancy or inability to give informed consent.
Patients were randomly allocated to thrombolysis or conventional treatment. Only patients allocated to thrombolytic treatment were asked for informed consent. ' 3 Patients were given intravenous heparin (5000 U), 100 The first radionuclide angiographic study was performed on 418 patients, the second study before hospital discharge on 361 patients, and a third study at three months follow up on 307 patients. In some patients radionuclide angiograms were not obtained because they had died, had had bypass surgery or recurrent myocardial infarction, or had refused to participate in further studies. Table 1 shows that the baseline characteristics and the infarct size determined by cumulative a-hydroxybutyrate release were similar in the randomised group of patients and in the subgroups with early and late radionuclide angiograms. There were no baseline differences between patients allocated to conventional treatment and those allocated to thrombolysis.
The left ventricular ejection fraction measured by radionuclide angiography was greater after thrombolysis in the total population and in various subgroups after two days, two weeks, and three months (table 2) ; however, the variability of the measurements was considerable (fig 1) . There were no changes in global left ventricular function in conventionally treated patients. In patients allocated to thrombolytic treatment there was a gradual improvement in left ventricular ejection fraction The total number of patients in each group is given as well as the numbers of patients with radionuclide angiograms. MI, mi.ocardial infarction. early and late measurements were similar in patients allocated to thrombolytic treatment whether or not they had had a previous myocardial infarction. The lack of statistical significance between the two treatment groups with a previous infarction was probably the result of the small numbers of patients.
An angiographic improvement in left ventricular Res, Simoons, van der Wall, et al groups were similar it is unlikely that baseline differences in left ventricular function or in haemodynamic state will account for the differences measured in the first few days of infarction.
Because patients died before radionuclide angiograms could be obtained or refused to undergo further investigations data were missed from this study. Data on patients who had bypass surgery or percutaneous transluminal coronary angiography elsewhere were also missed. It is unlikely, however, that the differences between conventionally treated patients and those allocated to thrombolysis are the result of selection bias. Baseline data in patients with and without follow up radionuclide angiograms were similar and the results of independent enzymatic measurements of infarct size were similar in patients allocated to thrombolysis and controls with and without radionuclide angiography (table  1) .
Most other randomised studies of intracoronary thrombolysis have not shown an effect on global left ventricular ejection fraction. 24-625 This is due in part to the small number of patients studied and probably to the long interval between onset of symptoms and thrombolytic treatment in most other studies. In the present study the interval was only 195 minutes (median), whereas it was 276 minutes in the Western Washington Trial which included 250 patients, 100 of whom underwent radionuclide angiography.4" One other randomised trial of 50 patients did show preservation of global left ventricular function after intracoronary thrombolytic treatment. 3 Mean treatment delay in that study was 240 minutes, and these workers also reported data on myocardial enzyme release that are compatible with a 40% reduction of myocardial infarct size. 8 The initial response to intracoronary treatment with streptokinase within the first few hours after the onset of myocardial infarction was cautious,26 but we believe that now there is sufficient evidence to prove that this treatment preserves global and regional left ventricular function and improves survival. The preservation of the left ventricular function persists for at least three months despite the higher rate of recurrent myocardial infarction after thrombolysis. Further studies should define the subgroups of patients that are most likely to benefit from this intervention. Furthermore, studies should be performed to compare the effects of different methods of thrombolysis-such as intravenous administration of streptokinase, intravenous infusion of acetylated streptokinase-plasminogen complex, or tissue plasminogen activator and intracoronary streptokinase-that can if necessary be followed by immediate mechanical perforation and percutaneous transluminal coronary angioplasty.
